Previous 10 | Next 10 |
home / stock / gnftf / gnftf news
Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland ); June 7 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with ra...
E xclusive worldwide rights licensed from Seal Rock Therapeutics for injectable formulation of ASK1 Inhibitor SRT-015 in acute liver disease Preclinical and clinical evidence support ASK1 inhibition as a relevant therapeutic strategy in ...
2023-05-29 15:00:00 ET The Institute for Clinical and Economic Review (ICER), the influential U.S. drug pricing watchdog, has warned about the affordability of two medications currently undergoing studies for liver disease, nonalcoholic steatohepatitis (NASH). Issuing a so-called access...
Q uorum of 29.54 % on first convening ; allowing approval of all the resolutions recommended by the Board of Directors Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); May 24 , 2023 - GENFIT (...
Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland ); May 23 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with ra...
Cash, cash equivalents and current financial assets totaled €128.6 million as of March 31, 2023 Lille (France); Cambridge, ( Massachusetts, United States); Zurich (Switzerland); May 11, 2023 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmace...
2023-05-11 16:04:46 ET Summary Results from the phase 3 ELATIVE study, using elafibranor to treat patients with primary biliary cholangitis, are expected to be released before end of Q2 of 2023. The primary biliary cholangitis market is expected to reach $1.7 billion by 2029. ...
Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland); May 9 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and sev...
GENFIT Announces Publication of Extra-Financial Performance Report 2022 Lille ( France ) ; Cambridge, ( Massachusetts, United States ) ; Zurich (Switzerland); April 2 7 , 202 3 - GENFIT (Nasdaq and Euronext: G...
Lille ( France ) ; Cambridge ( Massachusetts, United States ) ; Zurich (Switzerland) ; April 19 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with sev...
News, Short Squeeze, Breakout and More Instantly...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusi...
Ipsen’s Iqirvo ® (elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC) First-ever drug developed in-house by GENFIT to achieve U.S. FDA’s approval GENFIT is eligible to ...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed its presence ...